The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

and Major Depressive Disorder (MDD) with acute suicidal ideation or behavior. We offer Spravato intranasal esketamine and intramuscular ketamine treatment therapy to patients in western North ...

I specialize in treating patients with Mood Depressive ... and accept most major insurance plans. We are a leading provider of Transcranial Magnetic Stimulation (TMS) and esketamine nasal spray ...